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Abstract
OBJECTIVE—Comparison of studies evaluating patient-to-patient transmission of organisms is
difficult, given the lack of standardized criteria. We used fluoroquinolone-resistant Escherichia
coli (FQREC) as a model to characterize variability in definitions of relatedness across studies and
to evaluate the resultant impact on study conclusions.
DESIGN—Narrative review and cohort study.
METHODS—The narrative review compared relatedness criteria across studies of FQREC.
Additionally, an existing database was used to compare relatedness of isolates on the basis of
molecular criteria alone versus molecular plus clinical criteria with different temporal cutoffs
(hospitalization overlap of ≥ 1 day or allowance for nonoverlap of hospitalization dates of ≤7 days
or ≤30 days).
RESULTS—Forty-six articles met narrative review inclusion criteria. Sixteen studies exclusively
utilized molecular criteria to define relatedness. Thirty studies included molecular and clinical
criteria. Of these, 6 included temporal data (ie, time period of isolate identification), 10 included
patient location, and 14 included proximity and temporal criteria. For the database analysis, 353
patients were colonized with FQREC. There were 2 main clusters containing 48 and 17 related
isolates within 49 pulsed-field gel electrophoresis types. Among the clusters, 18.4% of isolates
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were related by molecular criteria. Incorporating clinical criteria, fewer isolates were considered
related: 5.7% of isolates using 30-day criteria, 3.1% using 7-day criteria, and 1.4% using 1-day
overlap.
CONCLUSIONS—There is considerable variability in definitions of relatedness of FQREC.
Utilizing molecular criteria alone to define relatedness overestimates transmission compared with
definitions including clinical criteria. Standard definitions of relatedness in studies of
antimicrobial-resistant organisms are needed.
Increasing antimicrobial resistance is a pressing public health crisis.1 In order to develop
effective infection control strategies, improved understanding of the relative contribution of
patient-to-patient transmission versus selection pressure (ie, antimicrobial use) to the
emergence of antimicrobial-resistant organisms is needed. Several studies have assessed
organism relatedness in order to determine the relative importance of patient-to-patient
transmission.2–4 However, there is no standard definition for patient-to-patient transmission
across studies. Some studies have used exclusively molecular criteria to determine genetic
relatedness and used genetic relatedness alone as a suggestion of patient-to-patient
transmission.5,6 Other studies employing more rigorous definitions have required genetic
relatedness along with clinical relatedness characteristics, such as overlap in hospital stay of
varying durations or location proximity among subjects.7,8 The degree of variability in
definitions of patient-to-patient transmission across studies has not been assessed, and the
impact of this variability on study conclusions is unknown, making comparisons across
studies difficult.
In this study, we used fluoroquinolone-resistant Escherichia coli (FQREC) as a model to
address these broader questions. Our goal in this study was to conduct a narrative review of
the literature to characterize differences in definitions of relatedness across studies of
FQREC. In addition, we sought to use an existing research database9 to evaluate the impact
of different definitions of relatedness on study conclusions regarding relatedness of FQREC.
METHODS
Narrative Review
A search of PubMed, the Cochrane database, Medline, and Google scholar was conducted
for articles of all study designs focusing on patient-to-patient transmission of FQREC. The
search terms used included “fluoroquinolone-resistant E. coli + pulsed-field gel
electrophoresis,” “fluoroquinolone-resistant E. coli + relatedness,” “fluoroquinolone-
resistant E. coli + patient transmission,” “fluoroquinolone-resistant E. coli + ribotyping,”
“fluoroquinolone-resistant E. coli + multilocus enzyme electrophoresis,” and
“fluoroquinolone-resistant E. coli + PCR.” Each of the previous searches was repeated,
substituting “quinolone-resistant E. coli” for “fluoroquino-lone-resistant E. coli.” The search
was limited to articles published in the English language involving human subjects. The
search was further enhanced by reviewing the bibliography of included articles to find
studies not previously identified.
The abstract of every identified article was reviewed. Only those articles describing FQREC
isolates that also commented on transmission or relatedness in human subjects were further
analyzed. Since E. coli with different resistance mechanisms may have different
transmissibility, articles that specifically evaluated extended-spectrum β-lactamase (ESBL)–
producing E. coli were excluded. Because this review focused on patient-to-patient
transmission in the hospital setting, articles concerning transmission of FQREC within
agricultural settings and studies of exclusively outpatient populations were excluded.
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Specific data elements extracted included the year and site of study, study design, patient
population, number of human subjects, number of FQREC isolates included for genotypic
analysis, source of FQREC isolate (ie, blood, stool), presence of FQREC colonization versus
infection, type of molecular data employed to determine relatedness, criteria for molecular
relatedness, whether clinical epidemiologic data were considered in assessing relatedness,
number of related isolates determined by molecular criteria, and number of identified related
isolates determined by combining clinical and molecular criteria (if applicable).
Cohort Study
The second part of this study was a methodologic study of the impact of different definitions
of relatedness on determination of relatedness of FQREC. This analysis was based on a
previously described data set for a study conducted by the authors.9 As described previously,
this study was performed at 2 hospitals within the University of Pennsylvania Health
System: (1) the Hospital of the University of Pennsylvania, a 725-bed academic tertiary care
medical center; and (2) Penn Presbyterian Medical Center, a 344-bed urban community
hospital. All patients hospitalized at the 2 study sites were eligible for inclusion, provided
they had been hospitalized for at least 3 days. Perirectal swabs were obtained from eligible
subjects to detect FQREC colonization.10 Levofloxacin was used as a marker for
susceptibility to fluoroquinolones (FQs). The genetic relatedness of FQREC isolates was
determined by pulsed-field gel electrophoresis (PFGE). All subjects colonized with E. coli
demonstrating reduced FQ susceptibility (as determined by a levofloxacin minimum
inhibitory concentration ≥0.125 μg/mL) were included in this study and were considered
FQREC. Clinical data related to location of subjects in the hospital, date of culture, and
hospitalization dates were documented. The number (and proportion) of FQREC isolates
determined to be secondary to patient-to-patient transmission on the basis of different
criteria was compared, as follows: (1) genetic criteria: genetic relatedness was determined
by isolates that had 80% or greater similarity by PFGE; and (2) clinical criteria: temporal
overlap of hospitalization of at least 1 day, allowance for nonoverlap of hospitalization dates
of 7 days or fewer, and allowance for nonoverlap of hospitalization dates of 30 days or
fewer.




We identified 706 articles on the basis of the above search criteria. All abstracts were
reviewed for content. Duplicates and ineligible articles based on the criteria detailed in
“Methods” were excluded, leaving 75 articles. These articles were reviewed in full, and
ineligible articles were excluded, so that 46 articles remained. The bibliographies of these
articles were reviewed, with 7 additional relevant articles identified. However, none of these
articles met inclusion criteria.
Figure 1 and Table 1 show a flow diagram and summary of the included articles,
respectively. Sample sizes for molecular analysis ranged from 4 to 353 FQREC isolates.
Thirty-nine of the studies employed PFGE, with definitions of criteria for molecular
relatedness ranging from 67% to 100% similarity. Seven studies employed random
amplification of polymorphic DNA typing, with criteria for molecular relatedness including
no band difference, 2 or fewer band difference, and similarity coefficient (SAB) values of
90% or greater. The molecular methods utilized in the remaining studies were as follows
(molecular criteria for relatedness in parentheses): 2 studies used enterobacterial repetitive
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intergenic consensus–polymerase chain reaction (PCR; <2 band difference or identical), 2
studies used automated ribotyping (identical or unlisted criteria), 2 studies used repetitive
sequence–based PCR (≥95% similarity or unlisted criteria), 1 study used infrequent
restriction site PCR (unlisted criteria), and 1 study used single-enzyme amplified fragment
length polymorphism (≥95% similarity).
Of the included studies, 16 exclusively utilized molecular criteria in their definition of
relatedness. Thirty studies included a combination of molecular and clinical criteria. Of
these, 6 studies included information on the date or time period of identification of the
isolates. Temporal criteria ranged from isolates collected during the same year to those
identified as isolated on the same day of hospitalization. Ten of 30 studies included
information on the location of the subjects. The proximity factors used ranged from noting
that isolates were collected from the same country to identifying the individual room and
nursing staff caring for the subject. Finally, 14 studies used both proximity and temporal
criteria. However, while these studies enumerated the clinical criteria used, the majority did
not define which isolates the authors qualified as responsible for patient-to-patient
transmission.
Cohort Study
As described previously,9 a total of 353 patients were identified as colonized with FQREC
in the prior study and were included in this study. Table 2 shows a summary of the results.
Among the 353 FQREC, there were 49 PFGE types. There were 2 main clusters: 1 cluster
contained 48 isolates (12a–12f cluster), and the other contained 17 isolates (16a–16c
cluster). Among the 2 large clusters, by PFGE (ie, molecular criteria), 48 + 17 isolates (n =
65) out of 353 (18.4%) isolates would be considered related. However, using a combination
of molecular criteria and clinical criteria, the n (%) that would be classified as related is
substantially lower (Table 2).
DISCUSSION
In this study, we provide a narrative review of the literature on patient-to-patient
transmission of FQREC and evaluate the impact of different definitions of relatedness on
study conclusions. In the narrative review, we found considerable variation in the definitions
used to report relatedness in the medical literature. In our analysis of a preexisting data set,
we found that employing different criteria for relatedness resulted in substantively different
study conclusions.
Our study provides a comprehensive comparison of different definitions of antimicrobial-
resistant organism relatedness across studies. Of the reviewed studies, more than half
exclusively used molecular criteria to define relatedness. Among those studies that also
incorporated clinical criteria, the specific criteria employed were oftentimes not clearly
delineated, and there was substantial variability in clinical criteria used. The high degree of
variability found in this narrative review emphasizes the lack of a standard epidemiologic
definition of relatedness. The concern with this degree of variability is that it makes
comparison across studies difficult. Studies utilizing purely molecular approaches are likely
to report falsely high patient-to-patient transmission rates, since patients hospitalized months
or even years apart with genetically similar isolates are unlikely to represent true person-to-
person transmission. For example, patients with nonoverlapping hospitalization might have
molecularly indistinguishable isolates secondary to acquisition of dominant strains that exist
in the community. On the other hand, more rigorous definitions requiring genetic relatedness
along with clinical criteria (eg, overlap in hospital stay) might miss transmission events
should an intermediate (ie, hospital employee or environmental source) be involved. While
additional studies are necessary to identify the most accurate definition of relatedness of
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antimicrobial-resistant organisms, this review highlights the importance of standardizing
reporting of relatedness in order to allow for comparison of studies and more accurately
determine the relative importance of patient-to-patient transmission.
In the second part of the study, we found that the relatedness rates of FQREC differ
significantly if molecular criteria alone are utilized versus a combination of molecular and
various clinical criteria. A combination of molecular criteria and moderately stringent
clinical variables will likely provide a more accurate estimate of true cases of patient-to-
patient transmission of FQREC. We propose that, in addition to molecular criteria, the
definition of patient-to-patient transmission for future studies should include 30-day criteria,
as defined in our study. We believe that this temporal criteria will appropriately exclude
genetically similar isolates from patients who have been hospitalized months to years apart
(and therefore are unlikely to be representative of true patient-to-patient transmission) but
will allow for enough time to account for potential transfer of isolates between intermediates
(eg, healthcare workers). Of note, these findings are not limited to FQREC; a study in
imipenem-resistant Pseudomonas aeruginosa showed variability in estimated rates of
relatedness when utilizing strictly molecular criteria versus a combination of molecular and
clinical criteria.11 However, other studies by the same authors in ESBL-producing E. coli
and Klebsiella pneumoniae did not show a similar discrepancy between relatedness as
defined by hospital overlap and PFGE results.2,3 This implies that criteria for the definition
of relatedness must be independently investigated for each organism and that optimal
infection control interventions may differ among gram-negative organisms.
There are several potential limitations of our study. The study was carried out in a university
health system and might not be generalizable to other settings. In addition, future studies
that include evaluation of environmental samples would help to elucidate the role of the
environment in the transmission of FQREC and define optimal overlap periods.
In conclusion, our study reveals the considerable variation in definitions used to report
relatedness of FQREC. In addition, it demonstrates that use of different criteria results in
substantial differences in estimated relatedness rates. Future studies are needed to determine
the most accurate criteria for defining relatedness for specific antimicrobial-resistant
organisms. Standardized definitions of relatedness will allow for future comparisons to be
made among studies, subsequent determination of the relative importance of patient-to-
patient transmission in acquisition of specific antimicrobial-resistant organisms, and,
ultimately, more efficient allocation of resources toward infection control interventions.
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Summary of the articles included in the narrative review. The number of articles of each
type is shown in parentheses. PFGE, pulsed-field gel electrophoresis; RAPD, random
amplification of polymorphic DNA. a = studies that utilized enterobacterial repetitive
intergenic consensus–polymerase chain reaction (PCR), repetitive sequence–based PCR,
infrequent restriction site PCR, and single enzyme amplified fragment length polymorphism.
b = study that utilized a combination of repetitive element–based PCR profiling, multilocus
sequence typing, and PFGE. c = study that utilized a combination of ribotyping followed by
PFGE. d =studies that utilized a combination of PFGE and plasmid typing, PFGE and
automated ribotyping, and enterobacterial repetitive intergenic consensus–PCR.
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Isolates meeting criteria for patient-to-patient transmission
No. %
12a–12f cluster 48
 PFGE 48 100
 0 daya 2 4.2
 7 dayb 4 8.3
 30 dayc 10 20.8
16a–16c cluster 17
 PFGE 17 100
 0 daya 3 17.6
 7 dayb 7 41.2
 30 dayc 10 58.8
Total samples 353
 PFGE 65 18.4
 0 daya 5 1.4
 7 dayb 11 3.1
 30 dayc 20 5.7
NOTE. PFGE, pulsed-field gel electrophoresis.
a
Genetically related isolates collected from subjects with temporal overlap of hospitalization of at least 1 day.
b
Genetically related isolates collected from subjects with hospitalization dates separated by no more than 7 days.
c
Genetically related isolates collected from subjects with hospitalization dates separated by no more than 30 days.
Infect Control Hosp Epidemiol. Author manuscript; available in PMC 2014 April 10.
